Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Cash from Operations (2020 - 2025)

Historic Cash from Operations for LifeStance Health (LFST) over the last 6 years, with Q3 2025 value amounting to $27.3 million.

  • LifeStance Health's Cash from Operations rose 2009.07% to $27.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.9 million, marking a year-over-year increase of 14442.73%. This contributed to the annual value of $107.3 million for FY2024, which is 73527.6% up from last year.
  • Latest data reveals that LifeStance Health reported Cash from Operations of $27.3 million as of Q3 2025, which was up 2009.07% from $64.4 million recorded in Q2 2025.
  • LifeStance Health's Cash from Operations' 5-year high stood at $64.4 million during Q2 2025, with a 5-year trough of -$25.4 million in Q3 2023.
  • For the 5-year period, LifeStance Health's Cash from Operations averaged around $16.0 million, with its median value being $9.9 million (2021).
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 54249.56% in 2023, then skyrocketed by 1025207.37% in 2024.
  • Over the past 5 years, LifeStance Health's Cash from Operations (Quarter) stood at $30.6 million in 2021, then rose by 17.24% to $35.9 million in 2022, then crashed by 53.24% to $16.8 million in 2023, then soared by 271.04% to $62.3 million in 2024, then plummeted by 56.21% to $27.3 million in 2025.
  • Its last three reported values are $27.3 million in Q3 2025, $64.4 million for Q2 2025, and -$3.1 million during Q1 2025.